The Therapeutic Products Act (TPA) entered into force two years ago with the objectives of accelerating market approvals and patient access to innovative products. What has been the experience since the revision date, specifically in the context of Covid-19?
The 13th ExEx symposium focuses on the TPA key aspects towards innovation and the meaning of global synergies, including the interaction of Swissmedic with international Health Authorities.
Join SwAPP us on-line, gain understanding and exchange on the following:
- Key aspects of the Swiss TPA towards innovation
- Synergy & collaboration at international level
- Safety signals management
- Tissue-agnostic approach in oncology
- Developing therapies in emergency situation
April 29, 2021 @ 1:00 pm